<?xml version="1.0" encoding="UTF-8"?>
<p>There are no therapeutic agents that have been approved to treat nCOVID-19. Various medicines including immunomodulatory or antiviral drugs such as remdesivir, favipiravir, ribavirin, chloroquine, hydroxychloroquine, azithromycin, nitazoxanide, teicoplanin etc. have been advised as potential investigational drugs, many of which are now being studied in animals and humans (Wang et al., 
 <xref rid="B186" ref-type="bibr">2020b</xref>; WHO, 
 <xref rid="B195" ref-type="bibr">2020c</xref>). On March 28, 2020, the Food and Drug Administration (FDA) gave an emergency use authorization (EUA) for emergency use of oral administrations of chloroquine phosphate and hydroxychloroquine sulfate to treat SARS-CoV-2 infection (FDA, 
 <xref rid="B62" ref-type="bibr">2020</xref>). Along with oxygen and mechanical ventilation, a guideline has also been published by Belgium which involved recommendations from four other European countries, including Switzerland, Netherlands, France, and Italy that recommended the use of remdesivir, lopinavir/ritonavir, tocilizumab, and chloroquine or hydroxychloroquine (Sciensano, 
 <xref rid="B162" ref-type="bibr">2020</xref>). In addition, Japan and China approved the use of favipiravir (an antiviral agent) to treat influenza, which is now under investigation to treat nCOVID-19 (Fujifilm, 
 <xref rid="B67" ref-type="bibr">2020</xref>).
</p>
